PE  Merlin Nexus

http://www.merlinnexus.com





     Office Locations:

424 West 33rd St., Suite 330
New York, NY 10001
Phone: 646-227-5270

 

Stages:

  • Middle Market


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    Merlin Nexus is a company focused on crossover private equity investing in the life sciences industry. Merlin Nexus invests globally in private and public healthcare companies. With its first fund launched in 2001 by Dominique Semon, Merlin Nexus now has several crossover private equity funds and a public-only fund, with commitments totaling $200 million. The Merlin Nexus objective is to realize long-term capital appreciation from investments in: Late-stage private companies; PIPEs (Private Investments in Public Equity); and select, long-term, open market investments. Unlike venture capital funds, Merlin Nexus funds are distinguished by relatively high liquidity and by short, 5-year maturities. The firm targets for each private investment a potential for liquidity within 24 months after initial investment, as well as a 2-3 times return on invested capital.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or New York Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Alberto Bianchinotti Chief Financial Officer
    Christian Richard Head of Research
    Dominique Semon Chief Investment Officer

     

    Portfolio companies include:


      Bioenvision
        web link


      Cytogen
        web link


      Pharmion
        web link


      Photomedex
        web link


      Salient Surgical
        web link


     

    Recent News: